Evolution of Clinical and Molecular Responses to Bexarotene Treatment in Cutaneous T-Cell Lymphoma

Abstract

Background: The mechanisms of action of bexarotene are not well understood. Methods: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Thirty-five patients were included. Twenty-three were treated with bexarotene for more than 3 months (300 mg/m²). In 7 patients, phototherapy was given with bexarotene. Results: Dominant T-cell clones were observed in 11 patients in peripheral blood and in 19 patients in skin. Our results demonstrate no significant evolution of T-cell clones either in skin or peripheral blood. Furthermore, the detection of T-cell clones in peripheral blood before starting bexarotene was significantly associated with the progression of the disease. UV therapy given with bexarotene significantly improved therapeutic response without any correlation with T-cell clones. Conclusion: This is the first study on the evolution of the T-cell clone in blood and skin in CTCL patients during bexarotene therapy.